Inogen, Inc. (INGN)

Inogen's stock price has fluctuated over the past six months, with a price of $6.33 as of April 10, 2026, and a 52-week range between $5.34 and $9.13. Key events impacting the stock include the release of the Fourth Quarter and Full Year 2025 financial results, leadership appointments, the appointment of Vafa Jamali to the Board of Directors, the authorization of a $30 million share repurchase program, and the reported exit of Philips from the portable oxygen concentrator market.

Inogen's demand exhibits seasonality, with the second and third quarters typically being the strongest. The first quarter is generally weaker, especially in the direct-to-consumer channel. International revenues can be erratic due to distributor size and timing, and unfavorable foreign exchange rates can hinder revenue growth.

Inogen, Inc. is a global medical technology company focused on developing, manufacturing, and marketing respiratory health products for homecare settings. Their primary products include portable oxygen concentrators (POCs) like the Inogen One and Inogen Rove, as well as stationary oxygen concentrators, CPAP masks, and airway clearance devices. Inogen also rents its products directly to patients.

Inogen markets its products in the United States and internationally. In 2025, 45.0% of revenue came from U.S. sales, 15.0% from U.S. rentals, and 40.0% from international sales. They collaborate with Yuwell for distribution in the United States and Asia, and have a European presence through Inogen Europe B.V. The corporate office is located in Beverly, Massachusetts.

Inogen is recognized as a leading global medical technology company in the homecare respiratory market, known for its portable oxygen concentrators. The company's brand reputation has been positively impacted by its strong financial turnaround, the competitor market exit, and its expanding product portfolio.

Inogen, Inc. has a mixed ownership structure. Institutional investors hold a substantial 74.82% of the company's shares, with mutual funds representing 41.89% of that. Insiders hold approximately 1.41% to 2.86%, and retail investors hold approximately 52.54% of the stock.